Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
pubmed:
24
2
2021
medline:
24
2
2021
entrez:
23
2
2021
Statut:
epublish
Résumé
There is an urgent need to understand the nature of immune responses generated against SARS-CoV-2, to better inform risk-mitigation strategies for people living with HIV (PLWH). Although not all PLWH are considered immunosuppressed, residual cellular immune deficiency and ongoing inflammation could influence COVID-19 disease severity, the evolution and durability of protective memory responses. Here, we performed an integrated analysis, characterizing the nature, breadth and magnitude of SARS-CoV-2-specific immune responses in PLWH, controlled on ART, and HIV negative subjects. Both groups were in the convalescent phase of predominately mild COVID-19 disease. The majority of PLWH mounted SARS-CoV-2 Spike- and Nucleoprotein-specific antibodies with neutralizing activity and SARS-CoV-2-specific T cell responses, as measured by ELISpot, at levels comparable to HIV negative subjects. T cell responses against Spike, Membrane and Nucleocapsid were the most prominent, with SARS-CoV-2-specific CD4 T cells outnumbering CD8 T cells. Notably, the overall magnitude of SARS-CoV-2-specific T cell responses related to the size of the naive CD4 T cell pool and the CD4:CD8 ratio in PLWH, in whom disparate antibody and T cell responses were observed. Both humoral and cellular responses to SARS-CoV-2 were detected at 5-7 months post-infection, providing evidence of medium-term durability of responses irrespective of HIV serostatus. Incomplete immune reconstitution on ART and a low CD4:CD8 ratio could, however, hamper the development of immunity to SARS-CoV-2 and serve as a useful tool for risk stratification of PLWH. These findings have implications for the individual management and potential effectiveness of vaccination against SARS-CoV-2 in PLWH.
Identifiants
pubmed: 33619489
doi: 10.1101/2021.02.15.431215
pmc: PMC7899453
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Medical Research Council
ID : MR/L018942/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008614/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R008698/1
Pays : United Kingdom
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Competing interests: The authors have declared that no conflict of interest exists.
Références
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Nature. 1998 Dec 17;396(6712):690-5
pubmed: 9872319
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Clin Infect Dis. 2011 Dec;53(11):1120-6
pubmed: 21998278
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Cell Rep. 2021 Mar 23;34(12):108890
pubmed: 33713594
PLoS Med. 2012;9(3):e1001194
pubmed: 22448150
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33533915
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
PLoS Pathog. 2020 Sep 24;16(9):e1008817
pubmed: 32970782
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Immunol. 2011 Jun 15;186(12):7264-8
pubmed: 21576510
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Sci Immunol. 2020 Jul 17;5(49):
pubmed: 32680954
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Leukemia. 2021 Jan;35(1):289-292
pubmed: 33299142
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
J Infect Dis. 2015 Jun 1;211(11):1726-34
pubmed: 25489001
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Front Immunol. 2020 Dec 09;11:571481
pubmed: 33362759
Front Immunol. 2017 Oct 23;8:1380
pubmed: 29109730
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Infect Dis. 2020 Jul;96:148-150
pubmed: 32335339
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Lancet HIV. 2021 Jan;8(1):e24-e32
pubmed: 33316211
Immunity. 2020 Nov 17;53(5):925-933.e4
pubmed: 33129373
Blood. 2012 Aug 2;120(5):985-93
pubmed: 22692510
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7239-44
pubmed: 15872023
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Viruses. 2020 Nov 09;12(11):
pubmed: 33182268
AIDS. 2018 Jul 31;32(12):1563-1569
pubmed: 29762172
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
HIV Med. 2014 Jan;15(1):40-9
pubmed: 24007533
J Infect Dis. 2015 Jun 15;211(12):1959-68
pubmed: 25556252
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Immunol Rev. 2017 Jan;275(1):33-48
pubmed: 28133792
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
J Immunol. 2013 Sep 1;191(5):2194-204
pubmed: 23918986
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
AIDS. 2020 Oct 1;34(12):1775-1780
pubmed: 32773471
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
J Clin Invest. 1995 May;95(5):2061-6
pubmed: 7738173
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
PLoS Pathog. 2021 Jul 16;17(7):e1009761
pubmed: 34270631
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Nat Microbiol. 2021 Jan;6(1):51-58
pubmed: 33199863
BMJ. 2009 Jan 26;338:a3172
pubmed: 19171560
Nat Rev Immunol. 2016 Feb;16(2):102-11
pubmed: 26781939
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Sci Immunol. 2020 Dec 23;5(54):
pubmed: 33361161
J Pathol. 2008 Jan;214(2):231-41
pubmed: 18161758
J Clin Invest. 2020 Dec 1;130(12):6477-6489
pubmed: 32833687
Curr HIV/AIDS Rep. 2008 Feb;5(1):13-9
pubmed: 18417030
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
HIV Med. 2020 Oct;21(9):567-577
pubmed: 32671970
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
J Immunol Methods. 2007 Sep 30;326(1-2):93-115
pubmed: 17707394
Nat Biotechnol. 1997 Sep;15(9):871-5
pubmed: 9306402
HIV Med. 2021 May;22(5):372-378
pubmed: 33368966
Nature. 2019 Apr;568(7751):244-248
pubmed: 30836379
Immunity. 2020 Oct 13;53(4):864-877.e5
pubmed: 32791036
PLoS One. 2014 Jan 30;9(1):e85798
pubmed: 24497929
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Immunity. 2021 Jan 12;54(1):44-52.e3
pubmed: 33338412
Eur J Immunol. 2020 Dec;50(12):1998-2012
pubmed: 33073359
AIDS. 2019 Feb 1;33(2):259-268
pubmed: 30325781
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Rev Immunol. 2015 Mar;15(3):185-9
pubmed: 25677493